Introduction
============

Effective treatment of infections is compromised worldwide by the emergence of multidrug resistance (MDR). According to the European Centre for Disease Prevention and Control, MDR is defined as unsusceptibility to at least one agent in three or more of the specified antimicrobial categories used in treatment.[@b1-idr-10-479]

MDR Gram-negative bacteria (MDRGNB) have become a major public health threat, as there are fewer or even sometimes no effective antimicrobial agents available for infections caused by these bacteria.[@b2-idr-10-479] MDR organisms, such as MDR carbapenemase-producing *Klebsiella pneumoniae*, and *Acinetobacter* spp., can be resistant to all currently available antimicrobial agents. Sometimes, they may remain susceptible only to older, potentially more toxic agents, such as polymyxins, leaving limited and suboptimal options for treatment.[@b3-idr-10-479] The problem of increasing antimicrobial resistance is even more threatening when considering the very limited number of new antimicrobial agents in development.[@b4-idr-10-479]

Several biochemical mechanisms can account for the antimicrobial resistance in GNB. These mechanisms include the enzymatic degradation of antibacterial agents, as in case of β-lactam resistance due to β-lactamases or modification of the antimicrobial agent by modifying enzymes, as in the case of aminoglycosides. It may also result from the alteration of antimicrobial targets in such organisms, as the in case of topoisomerase IV gene mutations that mediate resistance to fluoroquinolones. Moreover, changes in bacterial membrane permeability to antibiotics caused by mutations resulting in the loss of outer-membrane porin or overexpression of an efflux pump can lead to resistance to many effective anti-microbials. Efflux pumps, which expel multiple kinds of antibiotics, are now recognized as major contributors to MDR in bacteria: they can pump out most of the antibiotics in use.[@b5-idr-10-479]

MDR has been reported to be highly prevalent among different clinical isolates in Egyptian patients;[@b6-idr-10-479],[@b7-idr-10-479] however, few studies have examined the underlying resistance mechanisms.[@b7-idr-10-479] Third-generation cephalosporins are among the most commonly used antibiotics in Egypt.[@b8-idr-10-479] Therefore, resistance to third-generation cephalosporin will present a major problem in infection control, especially if accompanied with MDR. The aim of the present study was to detect the prevalence, molecular mechanisms of resistance, and clonal relatedness of MDRGNB among third-generation cephalosporin-resistant GN clinical isolates from Egypt.

Materials and methods
=====================

Bacterial strains and antibiotic susceptibility testing
-------------------------------------------------------

A total of 118 GN clinical isolates collected during 2009--2010, previously identified with API 20E and API 20NE systems (BioMérieux, France) with an identity of not less than 80%, were included in this study. They were selected from our culture collection based on their resistance to at least one of the third-generation cephalosporins. All isolates were from children with suspected infections in Abu El-Rish Children's Hospital, Cairo, Egypt.[@b9-idr-10-479] The isolates had been taken from different specimens: blood (n=3), catheter tips (n=3), cerebrospinal fluid (n=8), ear discharge (n=1), endotracheal tubing (n=20), midline subumbilical gaps (n=1), peritoneal discharge (n=4), pus (n=4), sputum (n=18), stool (n=9), urine (n=43), and wounds (n=5). All experiments in this study were conducted in accordance with and approval of the ethical committee at the Faculty of Pharmacy, Cairo University.

The antibiotic susceptibility of each isolate against its assigned categories of antimicrobials, as suggested by Magiorakos et al,[@b1-idr-10-479] was determined using Kirby--Bauer disk diffusion method following Clinical and Laboratory Standards Institute guidelines.[@b10-idr-10-479] *Stenotrophomonas maltophilia* was tested against the antimicrobial categories suggested by Milne and Gould.[@b11-idr-10-479] The antibiotics included in the study were gentamicin 10 μg, tobramycin 10 μg, amikacin 30 μg, ciprofloxacin 5 μg, cefoxitin 30 μg, piperacillin 100 μg, piperacillin--tazobactam 100 and 10 μg, sulfamethoxazole--trimethoprim 1.25 and 23.75 μg, imipenem 10 μg, ofloxacin 5 μg, cefepime 30 μg, aztreonam 30 μg, ampicillin--sulbactam 10 μg each, cefotaxime 30 μg, and ceftazidime 30 μg (all Oxoid; Thermo Fisher Scientific, Waltham, MA, USA). Isolates were classified as MDR and non-MDR according to Magiorakos et al.[@b1-idr-10-479] Intermediate susceptibility to any tested antibiotic was counted as resistant during the classification.

Identification of efflux pump-mediated resistance using efflux-pump inhibitor-based microplate assays
-----------------------------------------------------------------------------------------------------

Chlorpromazine (CPZ; Hongda Pharmaceutical, Donggang, China) acts as an efflux-pump inhibitor in GN bacteria.[@b12-idr-10-479] The minimum inhibitory concentration (MIC) of CPZ was determined by the microdilution method as per Clinical and Laboratory Standards Institute guidelines in all tested MDR clinical isolates.[@b13-idr-10-479] Efflux-pump inhibitor-based microplate assays using half the minimum inhibitory concentration of CPZ were performed in 24-well microplates (Thermo Fisher Scientific). Negative bacterial growth in a well containing an antibiotic disk besides CPZ and positive growth in a well containing the same antibiotic disk alone indicated efflux pump-mediated resistance to that antibiotic.[@b14-idr-10-479]

Detection of antibiotic-resistance genes
----------------------------------------

Genomic DNA was extracted from MDR clinical isolates by the boiling method.[@b15-idr-10-479] Polymerase chain reaction (PCR) identification of aminoglycoside-resistance genes (*arm*A and *aac*(6′)-*Ib*), β-lactamase-resistance genes (*(bla*~TEM~, *bla*~SHV~, *bla*~CTX-M~ group 1 and group 9), metallo-β-lactamase-resistance genes (*bla*~IMP~, *bla*~VIM~, *bla*~SPM-1~, *bla*~NDM~, *bla*~OXA-23-like~) and quinolone-resistance genes (*qep*A, *qnr*A, *qnr*B and *qnr*S) was performed as previously described.[@b16-idr-10-479]--[@b23-idr-10-479] Sequences of the resistance-genes primers used in the study and their annealing temperatures are provided in [Table 1](#t1-idr-10-479){ref-type="table"}. When necessary, PCR products were purified with a GeneJet PCR purification kit (Thermo Fisher Scientific). PCR products of *aac*(6′)-*Ib* positives were analyzed further by digestion with BstF5I (Thermo Fisher Scientific) to detect the cr variant.[@b18-idr-10-479] The purified PCR products were sequenced by an ABI 3730 XL DNA sequencer (Thermo Fisher Scientific). Detection of similarity for nucleotide sequences was performed using the BLAST program (<http://www.ncbi.nlm.nih.gov/blast>) with default settings.

Detection of genetic diversity of MDR isolates using random amplification of polymorphic DNA
--------------------------------------------------------------------------------------------

Clonal relatedness between isolates from the same species was assessed by random amplification of polymorphic DNA (RAPD) using at least two primers for each tested species.[@b24-idr-10-479]--[@b27-idr-10-479] Sequences of RAPD primers used in the study are provided in [Table 1](#t1-idr-10-479){ref-type="table"}. Amplicons were separated by 1.5% agarose-gel electrophoresis using a GeneRuler 100 bp ladder (Thermo Fisher Scientific) as a molecular size standard in each gel. Gels were stained with ethidium bromide and photographed under ultraviolet transillumination. Gel images were analyzed by GelAnalyzer 2010. The absence or presence of a band of a certain size was recorded as 0 or 1. For each strain, the RAPD type was defined as the combined band patterns obtained with the tested primers. The relationship between the RAPD types of isolates of the same species were calculated by unweighted pair-group (UPG) averages and represented as a dendrogram using UPGMA algorithms. In any tested isolate, banding patterns differing by two or more bands represented different strains, while banding patterns that differed by fewer than two bands were the same strain.[@b25-idr-10-479]

Results
=======

Bacterial strains and antibiotic-susceptibility testing
-------------------------------------------------------

A total of 118 GN clinical isolates characterized as being resistant to at least one of the third-generation cephalosporins were included in the study, and 100 isolates (84.75%) were classified as MDR: *Acinetobacter baumannii* (13 of 15, 86.6%), *Escherichia coli* (37 of 38, 97.37%), *K. pneu-moniae* (21 of 22, 95.45%), *Pseudomonas aeruginosa* (17 of 26, 65.38%), *S. maltophilia* (three of four, 75%), and other Enterobacteriaceae (nine of 13, 69.23%). MDR and non-MDR distribution among third-generation cephalosporin-resistant GN clinical isolates from different infection sites is shown in [Figure 1](#f1-idr-10-479){ref-type="fig"}. The antibiotic-susceptibility profile of each tested isolate is shown in [Table S1](#SD2-idr-10-479){ref-type="supplementary-material"}.

*A. baumanii* isolates were resistant to most of the tested antibiotics. Imipenem was the most effective antibiotic against tested Enterobacteriaceae and *P. aeruginosa*. All *S. maltophilia* isolates were susceptible to ofloxacin, ciprofloxacin, cefepime, piperacillin, piperacillin--tazobactam and sulfamethoxazole--trimethoprim. The number of resistant isolates in every tested bacterial species for each of the tested antibiotics is shown in [Table 2](#t2-idr-10-479){ref-type="table"} and [Figure 2](#f2-idr-10-479){ref-type="fig"}.

Identification of efflux pump-mediated resistance using efflux-pump inhibitor-based microplate assays
-----------------------------------------------------------------------------------------------------

Efflux pump-mediated resistance was recorded in 46.1% (six of 13), 41.1% (seven of 17), 40.54% (15 of 37), 66.67% (14 of 21), 66.67% (two of three), and 66.67% (six of nine) of MDR *A. baumannii*, *P. aeruginosa*, *E. coli*, *K. pneumoniae, S. maltophilia*, and other Enterobacteriaceae, respectively. Efflux pump-mediated resistance for more than one antibiotic was recorded in five of 13 and nine of 21 of MDR *A. bauman-nii* and *K. pneumoniae*, respectively. However, this multidrug efflux pump-mediated resistance was of lower incidence in other tested species. The number of isolates in each tested species displaying different patterns of efflux-mediated resistance is shown in [Table 3](#t3-idr-10-479){ref-type="table"}. Efflux pump-mediated resistance to different antibiotics in each MDRGNB isolate is shown in [Table S2](#SD3-idr-10-479){ref-type="supplementary-material"}.

Antibiotic-resistance genes
---------------------------

The sequenced products were deposited in the GenBank under accession numbers KY640457--KY640597. The incidence of each tested gene in the different species of MDRGNB clinical isolates tested is recorded in [Table 4](#t4-idr-10-479){ref-type="table"}, and their distribution in the different MDRGNB isolates is shown in [Table S3](#SD4-idr-10-479){ref-type="supplementary-material"}. All detected *bla*~TEM~ were TEM1 variants, while, *bla*~SHV~ were SHV1, SHV11, SHV12, and SHV31 variants. Group 1 *bla*~CTX-M~ ESBL-resistance genes belonged to type CTXM15, while *bla*~CTX-M~ group 9 belonged to type CTXM14. The metallo-β-lactamase resistance genes *bla*~IMP~, *bla*~SPM-1~, and *bla*~NDM~ and quinolone-resistance genes: *qep*A and *qnr*A were not detectable in our tested MDRGNB clinical isolates.

Determination of genetic diversity of MDR isolates using RAPD
-------------------------------------------------------------

The number of clonal patterns detected in MDRGNB isolates was 34 of 37, ten of 13, 18 of 21, and 17 of 26 patterns in *E. coli*, *A. baumannii, K. pneumoniae*, and *P. aeruginosa* isolates, respectively. No predominant clonal type was detectable with *E. coli* or *P. aeruginosa* isolates. However, five of 13 of *A. baumannii* isolates belonged to two clonal types, and three of 21 of *K. pneumoniae* isolates belonged to one clonal type. Clonally identical isolates shared the same antibiotic-resistance pattern (8, 27, and 146; 150, and 179 in *A. baumanii* and 161, 163, and 223 in *K. pneumoniae*), although they had different infection sites. Phenograms constructed using UPGMA algorithms for MDR isolates are shown in [Figure S1](#SD1-idr-10-479){ref-type="supplementary-material"}.

Discussion
==========

Few reports are available on the prevalence and mechanisms of MDR in GNB in developing countries including Egypt.[@b6-idr-10-479],[@b7-idr-10-479] Therefore, our study was carried out to determine the prevalence, molecular resistance mechanisms, and clonal relatedness of MDRGNB among third-generation cephalosporin-resistant isolates from Egypt. Our findings showed that 84.75% of the third-generation cephalosporin-resistant isolates were classified as MDR, with the highest percentage of MDR recorded in *E. coli*, followed b*y K. pneumoniae* and *A. baumannii*. Various international surveys have reported an increase in the number of MDRGNB in the last few years.[@b28-idr-10-479]

One of the alarming results was the resistance of *A. baumanii* isolates to most of the antibiotics tested, including imipenem. Carbapenems are considered one of the last-resort antimicrobials for GNB,[@b29-idr-10-479] and resistance to carbapenems leaves few effective therapeutic options, such as polymyxins or tigecycline.[@b5-idr-10-479] This high level of imipenem resistance (ten of 13) may result from the high number of *bla*~OXA-23~-like genes detected among MDR *A. baumanii* (nine of 13), as previously reported.[@b5-idr-10-479] This is in accordance with the results of Al-Agamy et al from Egypt, where *bla*~OXA-23~ and *bla*~OXA-24~-like genes were found to be the most prevalent type of β-lactamase-encoding genes in *A. baumannii*.[@b30-idr-10-479] Efflux-mediated resistance accounted for this MDR phenotype in *A. baumannii* (six of 13), half of which (three of six) contained multidrug-efflux pumps that mediated resistance to gentamicin, ciprofloxacin, sulfamethoxazole--trimethoprim, and piperacillin. A previous study in Egypt reported a higher percentage of efflux pumps (77.8%) in *A. baumannii* isolates.[@b31-idr-10-479] In accordance with previous studies,[@b5-idr-10-479] aminoglycoside resistance was common among our isolates. This may have been due to the presence of *aac-(6*′*)-Ib* gene-and efflux pump-mediated gentamicin resistance in nine of 12 and five of 12 of aminoglycoside-resistant MDR *A. baumanii* isolates, respectively.

In agreement with the reported susceptibility pattern of *P. aeruginosa*,[@b5-idr-10-479] most of our isolates were sensitive to imipenem (84%) and piperacillin--tazobactam (73%). On the contrary, 65% of *P. aeruginosa* isolates were MDR, of which only 23.5% showed multidrug efflux-mediated resistance. This is in contrast to the known major contribution of efflux pumps in MDR *P. aeruginosa*.[@b5-idr-10-479] The metallo-β-lactamase-resistance gene *bla*~VIM~ was detected in one *P. aeruginosa* isolate. This represented 5.88% of MDR *P. aeruginosa* clinical isolates and 33.33% of *P. aeruginosa* isolates resistant to imipenem. Other studies in Egypt reported higher prevalence of *bla*~VIM~ in *P. aeruginosa* clinical isolates.[@b32-idr-10-479],[@b33-idr-10-479]

All our *S. maltophilia* isolates were sensitive to sulfamethoxazole--trimethoprim, the cornerstone in the treatment of this pathogen,[@b5-idr-10-479] and to the tested fluoroquinolones (ciprofloxacin and ofloxacin). Most isolates (three of four) were sensitive to β-lactam/β-lactamase inhibitor combinations. Fluoroquinolones and β-lactam/β-lactamase inhibitor combinations have been reported to be among the most effective agents against *S. maltophilia*.[@b5-idr-10-479] Although *S. maltophilia* are known to be aminoglycoside-resistant,[@b5-idr-10-479] only one isolate (of three) was resistant to the three tested aminoglycosides, and showed efflux-mediated resistance to aminoglycosides. Efflux pumps are one of the known resistance mechanisms in *S. maltophilia*.[@b5-idr-10-479] Predominant resistance to aztreonam, cephalosporins, and imipenem in *S. maltophilia*, has been reported in the literature.[@b5-idr-10-479]

About 76% of the MDR Enterobacteriaceae contained at least one of the tested β-lactam-resistance genes, where β-lactamases are commonly reported among Enterobacteriaceae.[@b5-idr-10-479] In addition, efflux-mediated resistance to piperacillin (β-lactam) was recorded in 47.5% of piperacillin-resistant MDR Enterobacteriaceae. This highlights the major role played by efflux pumps in resistance to β-lactams in MDR Enterobacteriaceae. A lower predominance of efflux pump-mediated resistance (39%) was reported among MDR *K. pneumoniae* isolates in Turkey.[@b34-idr-10-479]

The *bla*~TEM-1~ gene was common in our MDR Enterobacteriaceae isolates and was the only detected β-lactamase-resistance gene in 6% of them. This is in agreement with previous studies showing the high persistence of the *bla*~TEM-1~ gene among Enterobacteriaceae worldwide.[@b35-idr-10-479] The β-lactamase-resistance gene *bla*~SHV~ was detected in 28.3% of MDR Enterobacteriaceae and identified by sequencing as variants SHV1, SHV11, SHV12 and SHV31 in 79%, 10.5%, 5%, and 5% of *bla*~SHV~-positive isolates, respectively. This was in contrast to another study from Egypt that detected only SHV1 and SHV11 in 57% and 29% of *bla*~SHV~-containing isolates, respectively.[@b36-idr-10-479] To the best of our knowledge, this is the first report on the occurrence of SHV31 in MDR *K. pneumoniae* isolates from Egypt, Africa, and the Middle East. Isolates were recovered from an endotracheal tube specimen, and were also positive for *bla*~TEM-1~, *bla*~CTX-M-15~, *bla*~CTX-M-14~, *aac(6*′*)-Ib-cr, qnr*S, and multidrug efflux-mediated resistance. The SHV31 variant has limited dissemination worldwide. It has been detected only in *K. pneumoniae* in the Netherlands (2001), Brazil (2005--2007), Iran (2006--2007), and Taiwan.[@b37-idr-10-479]

ESBL-resistance genes *bla*~CTX-M-15~ and *bla*~CTX-M-14~ were detected in 60%, and 24% of our MDR Enterobacteriaceae. This is in agreement with the worldwide prevalence of CTXM15 and CTXM14.[@b38-idr-10-479] Our findings are comparable with another study conducted in Egypt on β-lactamase prevalence in Enterobacteriaceae.[@b39-idr-10-479] In a similar study conducted in India, 66% of third-generation cephalosporin-resistant *E. coli* and *K. pneumoniae* isolates had *bla*~CTX-M-15~.[@b40-idr-10-479] Moreover, *bla*~OXA-23~-like, mainly detectable in *A. baumannii*,[@b30-idr-10-479] was detected in two of 21 *K. pneumoniae* isolates. The detection of *bla*~OXA-23~-like in *K. pneumoniae* has previously been reported in the literature.[@b41-idr-10-479]

Fluoroquinolone resistance in Enterobacteriaceae results mainly from mutations in DNA gyrase and topoisomerase genes.[@b5-idr-10-479] It was surprising to detect the plasmid-mediated quinolone-resistance genes *(aac(6′)-Ib-cr, qnr*B, and *qnr*S) in 57.6% (19 of 33) and 83.33% (ten of 12) of quinolone-resistant MDR *E. coli* and *K. pneumoniae*, respectively. These determinants have been detected worldwide with high prevalence among *K. pneumoniae*.[@b42-idr-10-479] The *aac(6′)-Ib-cr* gene, which confers resistance to ciprofloxacin and norfloxacin besides aminoglycosides, was prevalent in MDR *E. coli* isolates (48.6%), although lower incidence has previously been detected in Egypt (23.3%).[@b43-idr-10-479]

The aminoglycoside-modifying enzyme (*aac (6′)-Ib*) was detected in 84.4% of aminoglycoside-resistant Enterobacteriaceae. The role of modifying enzymes in aminoglycoside resistance has been documented.[@b5-idr-10-479] However, efflux-mediated gentamicin resistance was detected in 26.6% of aminoglycoside-resistant MDR Enterobacteriaceae. This again reflects the growing role of efflux pumps in mediating MDR among members of Enterobacteriaceae in Egypt.

The copresence of different classes of resistance genes was common among our isolates ([Table S3](#SD4-idr-10-479){ref-type="supplementary-material"}). This is alarming, as it presents an antibiotic selection advantage for these isolates to predominate as MDR. It is also worth noting that 17 of the MDRGNB isolates carried none of the tested β-lactamase genes nor exhibited efflux pump-mediated resistance. It is likely that these isolates carry one or more β-lactamase genes not tested in this study or contain efflux pumps that could not be detected by the efflux-pump inhibitor used.

The MDR species tested were genotypically variable. This suggested that multiple subtypes of the species were involved in MDR and opposed the probability that MDR may have resulted from clonal spread. The only limitation of this study was the small number of isolates tested in some species, which made it difficult to draw solid conclusions about these organisms.

Conclusion
==========

MDR is predominant among third-generation cephalosporin-resistant GNB in Egypt. In most cases, resistance is caused by different mechanisms. This study highlighted the increasing role of efflux pumps and the increase in plasmid-mediated quinolone resistance among MDR Enterobacteriaceae. Therefore, new treatment strategies need to be implemented. The use of an efflux-pump inhibitor combined with old antibiotics can provide a possible treatment for infections caused by efflux-mediated resistant bacteria, maintaining the effectiveness of old antibiotics. Moreover, antibiotic misuse needs to be stopped to avoid the selection of MDR species.

Supplementary material
======================

###### 

Phenogram of different multidrug resistant isolates constructed using UPGMA algorithms based on RAPD analysis.

**Notes:** (**A**) Phenogram of *Escherichia coli* using three different primers; (**B**) phenogram of *Klebsiella pneumoniae* using three different primers; (**C**) phenogram of *Acinetobacter baumannii* using three different primers; (**D**) phenogram of *Pseudomonas aeruginosa* using two different primers.

**Abbreviations:** RAPD, random amplification of polymorphic DNA; UPGMA, unweighted pair group method with arithmetic mean.

###### 

Identification, source, susceptibility pattern, and multidrug-resistant phenotype of each tested isolate

  --
  --

**Notes:** Black cells, resistance to tested antibiotic; white cells, sensitive to tested antibiotic; gray cells, intermediate result to tested antibiotic.

**Abbreviations:** MDR, multidrug resistance; CN, gentamicin; AK, amikacin; TOB, tobramycin; OFX, ofloxacin; CIP, ciprofloxacin; FOX, cefoxitin; FEP, cefepime; PRL, piperacillin; PT, piperacillin--tazobactam; SXT, sulfamethoxazole--trimethoprim; IMP, imipenem; AO, aztreonam; AS, ampicillin--sulbactam; CTX, cefotaxime; CAZ, ceftazidime; ETT, endotracheal tube; CSF, cerebrospinal fluid.

###### 

Efflux-mediated resistance profile in each tested multidrug-resistant Gram-negative isolate

  --
  --

**Notes:** Black cells, presence of efflux-mediated resistance; white cells, absence of efflux-mediated resistance.

###### 

Distribution of different resistance genes in each tested multidrug-resistant Gram-negative clinical isolate

  --
  --

**Notes:**

Gene variants detected. Black cells, presence of resistance genes; white cells, absence of resistance genes.

The abstract for this study was published in the *International Journal of Medical and Health Sciences*, 2016;3(5).
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![Distribution of MDR and non-MDR phenotypes among third-generation cephalosporin resistant Gram-negative clinical isolates from different infection sites.\
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![Percentage of isolates resistant to each antimicrobial tested within the different bacterial species.\
**Abbreviations:** CN, gentamicin; AK, amikacin; TOB, tobramycin; OFX, ofloxacin; CIP, ciprofloxacin; FOX, cefoxitin; FEP, cefepime; PRL, piperacillin; PT, piperacillin--tazobactam; SXT, sulfamethoxazole--trimethoprim; IMP, imipenem; AO, aztreonam; AS, ampicillin--sulbactam.](idr-10-479Fig2){#f2-idr-10-479}

###### 

Primers used for detection of resistance genes and RAPD typing, annealing temperatures (T~a~), and expected product sizes

  Primer           Sequence (5′-3′)                                                  Target gene                                               T~a~   Product size        Reference
  ---------------- ----------------------------------------------------------------- --------------------------------------------------------- ------ ------------------- -------------------
  armA-F           ATT CTG CCT ATC CTA ATT GG                                        16S RNA methylase *armA*                                  55°C   315 bp              [@b16-idr-10-479]
  armA-R           ACC TAT ACT TTA TCG TCG TC                                                                                                                             
  aac(6′)-Ib-F     TTGCGATGCTCTATGAGTGGCTA                                           *aac(6*′*)-Ib*                                            54°C   482 bp              [@b18-idr-10-479]
  aac(6′)-Ib-R     CTCGAATGCCTGGCGTGTTT                                                                                                                                   
  MultiTSO-T-F     CATTTCCGTGTCGCCCTTATTC                                            TEM variants, including TEM1 and TEM2                     60°C   800 bp              [@b20-idr-10-479]
  MultiTSO-T-R     CGTTCATCCATAGTTGCCTGAC                                                                                                                                 
  MultiTSO-S-F     AGCCGCTTGAGCAAATTAAAC                                             SHV variants, including SHV1                              60°C   713 bp              [@b20-idr-10-479]
  MultiTSO-S-R     ATCCCGCAGATAAATCACCAC                                                                                                                                  
  MultiCTXMGp1-F   TTAGGAARTGTGCCGCTGYA[a](#tfn1-idr-10-479){ref-type="table-fn"}    Variants of CTXM group 1                                  60°C   688 bp              [@b20-idr-10-479]
  MultiCTXMGp1-R   CGATATCGTTGGTGGTRCCAT[a](#tfn1-idr-10-479){ref-type="table-fn"}                                                                                        
  MultiCTXMGp9-F   TCAAGCCTGCCGATCTGGT                                               Variants of CTXM group 9                                  60°C   561 bp              [@b20-idr-10-479]
  MultiCTXMGp9-R   TGATTCTCGCCGCTGAAG                                                                                                                                     
  MultiIMP-F       TTGACACTCCATTTACDG[a](#tfn1-idr-10-479){ref-type="table-fn"}      IMP variants                                              55°C   139 bp              [@b20-idr-10-479]
  MultiIMP-R       GATYGAGAATTAAGCCACYCT[a](#tfn1-idr-10-479){ref-type="table-fn"}                                                                                        
  MultiVIM-F       GATGGTGTTTGGTCGCATA                                               VIM variants                                              55°C   390 bp              [@b20-idr-10-479]
  MultiVIM-R       CGAATGCGCAGCACCAG                                                                                                                                      
  Spm-F            AAA ATC TGG GTA CGC AAA CG                                        SPM1                                                      52°C   271 bp              [@b23-idr-10-479]
  Spm-R            ACA TTA TCC GCT GGA ACA GG                                                                                                                             
  NDM-F            GGT TTG GCG ATC TGG TTT TC                                        NDM variants                                              52°C   621 bp              [@b21-idr-10-479]
  NDM-R            CGG AAT GGC TCA TCA CGA TC                                                                                                                             
  OXA-23-like-F    GAT CGG ATT GGA GAA CCA GA                                        OXA23-like                                                53°C   501 bp              [@b22-idr-10-479]
  OXA-23-like-R    ATT TCT GAC CGC ATT TCC AT                                                                                                                             
  qepA-F           GCA GGT CCA GCA GCG GGT AG                                        *qep*A                                                    60°C   199 bp              [@b17-idr-10-479]
  qepA-R           CTT CCT GCC CGA GTA TCG TG                                                                                                                             
  QnrA-F           AGAGGATTTCTCACGCCAGG                                              *qnr*A                                                    54°C   580 bp              [@b19-idr-10-479]
  QnrA-R           TGCCAGGCACAGATCTTGAC                                                                                                                                   
  QnrB-F           GGMATHGAAATTCGCCACTG[b](#tfn2-idr-10-479){ref-type="table-fn"}    *qnr*B                                                    54°C   264 bp              [@b19-idr-10-479]
  QnrB-R           TTTGCYGYYCGCCAGTCGAA[b](#tfn2-idr-10-479){ref-type="table-fn"}                                                                                         
  QnrS-F           GCAAGTTCATTGAACAGGGT                                              *qnr*S                                                    54°C   428 bp              [@b19-idr-10-479]
  QnrS-R           TCTAAACCGTCGAGTTCGGCG                                                                                                                                  
  208              ACGGCCGACC                                                        RAPD for *Pseudomonas aeruginosa*                         36°C                       
  272              AGCGGGCCAA                                                        36°C                                                             [@b24-idr-10-479]   
  ERIC1            ATGTAAGCTCCTGGGGATTCAC                                                                                                      35°C                       
  ERIC2            AAGTAAGTGACTGGGGTGAGCG                                            RAPD for *Klebsiella pneumoniae*                          25°C                       [@b25-idr-10-479]
  RAPD7            GTGGATGCGA                                                                                                                  35°C                       [@b26-idr-10-479]
  1247             AAGAGCCCGT                                                        RAPD for *Escherichia coli and Acinetobacter baumannii*   36°C                       
  1281             AACGCGCAAC                                                                                                                         [@b27-idr-10-479]   
  1283             GCGATCCCCA                                                                                                                                             

**Notes:**

Y = T or C; R = A or G; D = A or G or T;

M = A or C; H = A or C or T; Y = C or T.

**Abbreviation:** RAPD, random amplification of polymorphic DNA.

###### 

Resistance to different antibiotics in the tested species of Gram-negative clinical isolates

  Bacterial species                CN      AK      TOB     OFX     CIP     FOX     FEP     PRL     PT      SXT     IMP     AO      AS      CTX     CAZ
  -------------------------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  *Acinetobacter baumannii*        12/15   12/15   10/15   13/15   12/15   14/15   13/15   13/15   13/15   11/15   10/15   15/15   11/15   14/15   15/15
  *Citrobacter freundii*           2/4     0/4     2/4     0/4     0/4     1/4     1/4     2/4     1/4     1/4     0/4     2/4     2/4     1/4     2/4
  *Enterobacter cloacae*           1/3     1/3     1/3     0/3     1/3     2/3     1/3     1/3     1/3     1/3     1/3     1/3     2/3     1/3     1/3
  *Escherichia coli*               19/38   3/38    17/38   33/38   32/38   31/38   25/38   32/38   3/38    37/38   1/38    28/38   24/38   31/38   30/38
  *Klebsiella pneumoniae*          17/22   9/22    18/22   12/22   12/22   12/22   20/22   22/22   11/22   17/22   2/22    20/22   18/22   20/22   21/22
  *Morganella morganii*            1/2     0/2     0/2     0/2     0/2     1/2     0/2     0/2     0/2     1/2     0/2     0/2     1/2     0/2     0/2
  *Pseudomonas aeruginosa*         11/26   10/26   10/26   13/26   11/26   20/26   11/26   12/26   7/26    15/26   4/26    17/26   19/26   19/26   21/26
  *Proteus mirabilis*              0/2     0/2     0/2     1/2     0/2     0/2     0/2     1/2     1/2     1/2     0/2     2/2     1/2     1/2     1/2
  *Stenotrophomonas maltophilia*   1/4     1/4     1/4     0/4     0/4     4/4     0/4     0/4     0/4     0/4     3/4     3/4     1/4     3/4     3/4
  *Serratia marcescens*            1/2     2/2     1/2     0/2     0/2     1/2     0/2     2/2     0/2     1/2     0/2     0/2     1/2     2/2     1/2

**Abbreviations:** CN, gentamicin; AK, amikacin; TOB, tobramycin; OFX, ofloxacin; CIP, ciprofloxacin; FOX, cefoxitin; FEP, cefepime; PRL, piperacillin; PT, piperacillin--tazobactam; SXT, sulfamethoxazole--trimethoprim; IMP, imipenem; AO, aztreonam; AS, ampicillin--sulbactam; CTX, cefotaxime; CAZ, ceftazidime.

###### 

Number of isolates in each tested species displaying different patterns of efflux-mediated resistance

  Pattern                         *Acinetobacter baumannii*   *Citrobacter freundii*   *Escherichia coli*   *Enterobacter cloacae*   *Klebsiella pneumoniae*   *Morganella morganii*   *Pseudomonas aeruginosa*   *Proteus mirabilis*   *Stenotrophomonas maltophilia*   *Serratia marcescens*
  ------------------------------- --------------------------- ------------------------ -------------------- ------------------------ ------------------------- ----------------------- -------------------------- --------------------- -------------------------------- -----------------------
  No efflux-mediated resistance   7/13                        2/3                      22/37                0/1                      7/21                      0/1                     10/17                      1/2                   1/3                              0/2
  CN, CIP, SXT, PRL               3/13                        0/3                      1/37                 0/1                      3/21                      0/1                     0/17                       0/2                   0/3                              0/2
  CN, CIP, SXT                    1/13                        0/3                      0/37                 0/1                      1/21                      0/1                     1/17                       0/2                   0/3                              0/2
  CN, CIP, PRL                    1/13                        0/3                      0/37                 0/1                      1/21                      0/1                     0/17                       0/2                   0/3                              0/2
  CN, SXT, PRL                    0/13                        0/3                      0/37                 0/1                      1/21                      0/1                     0/17                       0/2                   0/3                              0/2
  CIP, SXT, PRL                   0/13                        0/3                      1/37                 0/1                      0/21                      0/1                     1/17                       0/2                   0/3                              0/2
  CN, CIP                         0/13                        0/3                      1/37                 0/1                      1/21                      0/1                     0/17                       0/2                   0/3                              0/2
  CN, PRL                         0/13                        0/3                      0/37                 0/1                      1/21                      0/1                     0/17                       0/2                   0/3                              0/2
  CIP, SXT                        0/13                        0/3                      1/37                 0/1                      0/21                      0/1                     0/17                       0/2                   0/3                              0/2
  CIP, PRL                        0/13                        0/3                      2/37                 0/1                      0/21                      0/1                     1/17                       0/2                   0/3                              0/2
  SXT, PRL                        0/13                        0/3                      1/37                 0/1                      1/21                      0/1                     1/17                       0/2                   0/3                              1/2
  CN                              0/13                        0/3                      0/37                 1/1                      1/21                      0/1                     0/17                       0/2                   1/3                              0/2
  CIP                             1/13                        0/3                      0/37                 0/1                      1/21                      0/1                     0/17                       0/2                   0/3                              0/2
  SXT                             0/13                        1/3                      5/37                 0/1                      1/21                      1/1                     1/17                       1/2                   0/3                              0/2
  PRL                             0/13                        0/3                      3/37                 0/1                      2/21                      0/1                     2/17                       0/2                   1/3                              1/2

**Abbreviations:** CN, gentamicin; CIP, ciprofloxacin; PRL, piperacillin; SXT, sulfamethoxazole--trimethoprim.

###### 

Resistance genes in the different species of multidrug-resistant Gram-negative clinical isolates

  Bacterial species                *armA*   *aac-Ib*   *aac-Ib-cr*   *bla*~TEM-1~   *bla*~SHV~                                        *bla*~CTX-M-15~   *bla*~CTX-M-14~   *bla*~IMP~   *bla*~VIM~   *bla*~SPM-1~   *bla*~OXA-23~   *qep*A   *qnr*A   *qnr*B   *qnr*S
  -------------------------------- -------- ---------- ------------- -------------- ------------------------------------------------- ----------------- ----------------- ------------ ------------ -------------- --------------- -------- -------- -------- --------
  *Acinetobacter baumannii*        0/13     9/13       0/13          7/13           3/13[a](#tfn6-idr-10-479){ref-type="table-fn"}    4/13              1/13              0/13         0/13         0/13           9/13            0/13     0/13     0/13     1/13
  *Citrobacter freundii*           0/3      0/3        0/3           1/3            1/3[b](#tfn7-idr-10-479){ref-type="table-fn"}     1/3               0/3               0/3          0/3          0/3            0/3             0/3      0/3      1/3      0/3
  *Enterobacter cloacae*           0/1      1/1        0/1           0/1            0/1                                               0/1               0/1               0/1          0/1          0/1            0/1             0/1      0/1      0/1      0/1
  *Escherichia coli*               1/37     2/37       18/37         22/37          0/37                                              23/37             8/37              0/37         0/37         0/37           0/37            0/37     0/37     0/37     1/37
  *Klebsiella pneumoniae*          0/21     8/21       8/21          12/21          17/21[c](#tfn8-idr-10-479){ref-type="table-fn"}   15/21             7/21              0/21         0/21         0/21           2/21            0/21     0/21     1/21     1/21
  *Morganella morganii*            0/1      0/1        0/1           0/1            0/1                                               0/1               0/1               0/1          0/1          0/1            0/1             0/1      0/1      0/1      0/1
  *Pseudomonas aeruginosa*         0/17     4/17       1/17          3/17           2/17[d](#tfn9-idr-10-479){ref-type="table-fn"}    5/17              1/17              0/17         1/17         0/17           0/17            0/17     0/17     0/17     0/17
  *Proteus mirabilis*              0/2      0/2        1/2           1/2            1/2[e](#tfn10-idr-10-479){ref-type="table-fn"}    1/2               0/2               0/2          0/2          0/2            0/2             0/2      0/2      0/2      0/2
  *Stenotrophomonas maltophilia*   0/3      0/3        0/3           0/3            0/3                                               0/3               0/3               0/3          0/3          0/3            0/3             0/3      0/3      0/3      0/3
  *Serratia marcescens*            0/2      0/2        0/2           0/2            0/2                                               0/2               1/2               0/2          0/2          0/2            0/2             0/2      0/2      0/2      0/2

**Notes:**

Two of three of the detected SHVs were the variant SHV1 and one of three the variant SHV11;

one detected SHV -- SHV1;

13 of 17 of the detected SHVs were SHV1, two of 17 SHV11, one of 17 SHV12, and one of 17 SHV31;

one of two of the detected SHVs was SHV1 and one of two SHV11;

one detected SHV -- SHV1.
